Endo Fibrates T2d Retinopathy Progression

---
name: endo-fibrates-t2d-retinopathy-progression
description: Suggests fibrates in addition to statins to reduce retinopathy progression in adults with type 2 diabetes and diabetic retinopathy. Triggers include: "Patient with T2D and diabetic retinopathy", "Considering fibrate for retinopathy protection", "Assessing retinopathy progression prevention in diabetes".
---

# Fibrates in addition to statins for diabetic retinopathy progression in type 2 diabetes

## STEP 1 — Gather Information
Confirm type 2 diabetes diagnosis, presence of diabetic retinopathy (via dilated eye exam or retinal photography), current statin use, triglycerides, renal function, liver enzymes, and contraindications to fibrate (active liver disease, gallbladder disease, hypersensitivity).  
**Action:** Proceed to step 2 if T2D and diabetic retinopathy are confirmed.

## STEP 2 — Rule In / Rule Out
Is the patient diagnosed with type 2 diabetes and has diabetic retinopathy?  
**Action:** If yes, proceed to step 3; if no, do not recommend fibrate for retinopathy protection.

## STEP 3 — Classify or Stratify
Assess statin therapy: if the patient is already on a statin, proceed to add fibrate; if not on a statin, consider initiating statin therapy per cardiovascular risk guidelines before adding fibrate.  
**Action:** Proceed to step 4 to decide on fibrate initiation.

## STEP 4 — Decide
Prescribe fenofibrate (the preferred fibrate) in addition to existing statin therapy to reduce retinopathy progression.  
**Action:** Initiate fenofibrate 145 mg daily (or equivalent) and monitor for efficacy and safety.

## Clinical Guardrails / Mimics / Pitfalls
Avoid gemfibrozil due to higher myopathy risk when combined with statins; monitor creatine kinase if muscle symptoms arise; assess renal function before and during therapy (dose adjust if eGFR <30 mL/min/1.73m²); do not use in active liver disease or unexplained persistent transaminase elevations; monitor for gallstones; fibrates do not replace statin therapy for cardiovascular risk reduction.

## Concrete Clinical Example
A 58-year-old man with type 2 diabetes (HbA1c 7.8%) on atorvastatin 20 mg daily presents with mild non‑proliferative diabetic retinopathy on fundus exam; after confirming no contraindications, fenofibrate 145 mg daily is added to his statin to slow retinopathy progression.

**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674